Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
about
NCI-60 Cell Line Screening: A Radical Departure in its Time.Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patientsCytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.Functional role of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in NSCLCPreanalytic parameters in epidermal growth factor receptor mutation testing for non-small cell lung carcinoma: A review of cytologic seriesThe feasibility of molecular testing on cell blocks created from brush tip washings in the assessment of peripheral lung lesions.Sensitization strategies in lung cancerMEK inhibitors against MET-amplified non-small cell lung cancerAnalysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma.Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.Wnt signaling as potential therapeutic target in lung cancer.Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.MicroRNA-targeted therapeutics for lung cancer treatment.Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice.Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic Non-Small Cell Lung Carcinoma (NSCLC).RhoA inhibits apoptosis and increases proliferation of cultured SPCA1 lung cancer cellsMetabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography.Lung Cancer Subtypes Generate Unique Immune Responses.The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Kinase-targeted cancer therapies: progress, challenges and future directions.Standardizing biomarker testing for Canadian patients with advanced lung cancer.[Overexpression of OLC1 in Lung Squamous Cell Carcinoma Tissues is Associated with Poor Prognosis of Patients].miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.Inhibiting TRK Proteins in Clinical Cancer Therapy.Galectin-3 activates TLR4/NF-κB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression.
P2860
Q30383428-9891C02D-65C7-444B-B138-F7F3401E26CFQ33688558-9603CA3B-5FC3-42FC-A0C2-3A4DC65A9E45Q36135533-1363B4F2-72A4-471D-99A2-1E3E9A57DA15Q36852170-5EA22867-FEBC-4238-A817-B23933411D28Q37269270-AD8BFFF8-1288-439B-A5E1-C91BF3D914A7Q37296060-A97603A5-5611-48DC-A2A6-DD4EB1864B59Q37329434-656D9C6D-4EEC-4A49-BF29-E52C3A2F5C4FQ37407122-E8948D22-FC6F-473E-8F42-8FCCC34DD438Q37427045-499687B5-0935-41D9-92D9-257522F83CEAQ37567731-C2109E3D-D161-488A-9742-0C124AFE44EAQ37665468-AECF5B84-1B08-4390-AD55-D360909EDE27Q38620198-C8E7D092-8558-403D-9551-78B4D7BE4B6EQ38653663-93E8E55B-BE51-458C-877C-3C5A830A45EAQ38735754-8FD205D6-EAA8-425A-834B-A1AECCD22325Q38899873-0BAA5118-E726-4EFF-AEE3-7B3DB6BDED17Q38961444-6ED86001-DD7C-4D1D-9F65-0F65B2BE9022Q39014580-EA603AD2-D34A-440D-8795-2C96315BBBD5Q39039088-C50BDE00-12EA-4F0D-A5E0-DB8ADE9ECF2FQ39123715-81847A0A-06CC-4138-AD3D-3A65D641FBC3Q40185703-5377CC86-AEBF-45C6-A17E-73FEB972E81FQ41986408-735F4810-2F66-4087-9E2B-6BD60D956903Q44508044-819E311D-205D-4E18-A128-E30BB573AE29Q45459148-D0022624-46C7-4847-B4A9-C2376F5CE7B8Q47138128-222D9ABC-6CF8-49DD-93C5-BB6FF07300B5Q49667322-43B32A0F-2830-4DC0-8958-AECF68F4AF04Q49887882-0EEC5850-F87E-4B58-8C63-207BC767F9FBQ52673091-3D51381C-CAEF-4E53-BF03-F1D6A9AB58B5Q53186371-964B4FE8-801F-4227-B3D9-EA14FBC236FAQ53189857-6FA35A49-03E1-4C6F-843B-87223647C948Q54117764-68E80B2D-959F-452C-9948-E544A098C48AQ55101189-1A67F7C5-F081-4E7E-872D-D6EB6A79654F
P2860
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
@ast
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
@en
type
label
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
@ast
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
@en
prefLabel
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
@ast
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
@en
P2093
P2860
P50
P1476
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
@en
P2093
Alice T Shaw
Daniel Morgensztern
David E Gerber
David Johnson
David R Spigel
Edward Garon
George R Simon
John Wrangle
Lecia V Sequist
Leora Horn
P2860
P356
10.1097/JTO.0000000000000405
P433
P577
2015-01-01T00:00:00Z